Literature DB >> 33674998

The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases.

Jesse Elliott1, George A Wells2,3, Doug Coyle2.   

Abstract

Mesh:

Substances:

Year:  2021        PMID: 33674998     DOI: 10.1007/s40273-021-01007-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  1 in total

1.  Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".

Authors:  Kelly Hollenack; Jade Marshall
Journal:  Pharmacoeconomics       Date:  2021-03-06       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.